Description
Mometasone Furoate is indicated for the treatment of symptoms of intermittent or persistent allergic rhinitis (previously classified as seasonal or perennial) according to the new classification proposed by the ARIA guidelines (Allergic Rhinitis and its Impact on Asthma for its acronym in English ), of adult patients, adolescents and children from 2 years of age. In patients with a history of moderate to severe symptoms of intermittent allergic rhinitis, prophylactic treatment with Mometasone furoate is recommended for two to four weeks prior to the expected onset of pollen season.
Mometasone Furoate Nasal Spray is also indicated for the treatment of symptoms associated with acute rhinosinusitis in patients from 12 years of age who do not present symptoms or signs of bacterial infection. It is also indicated as an associated treatment together with antibiotic therapy, for acute rhinosinusitis in adult patients and adolescents over 12 years of age.
Mometasone Furoate Nasal Spray is indicated for the treatment of symptoms associated with adenoid hypertrophy in children and adolescents from 2 years of age, such as nighttime snoring, nasal congestion, oral breathing, rhinorrhea and postnasal discharge.
Mometasone Furoate Nasal Spray is also indicated for the treatment of nasal polyps and associated symptoms including congestion and hyposmia in adult patients over 18 years of age.
Reviews
There are no reviews yet.